Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Veracyte Inc
(NQ:
VCYT
)
32.00
+0.94 (+3.03%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Veracyte Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Earnings Outlook For Veracyte
February 21, 2024
Via
Benzinga
Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
February 08, 2024
From
Veracyte, Inc.
Via
Business Wire
Veracyte Completes Acquisition of C2i Genomics
February 06, 2024
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics Platform
January 08, 2024
From
Veracyte, Inc.
Via
Business Wire
Veracyte: Q3 Earnings Insights
November 07, 2023
Via
Benzinga
Cathie Wood's Ark Invest Buys Over $92M Worth Of ProShares Bitcoin ETF, Sells Coinbase, Block And Palantir Shares
December 27, 2023
On Wednesday, Cathie Wood-led Ark Invest made a significant move in the cryptocurrency space, purchasing over $92 million worth of ProShares Bitcoin Strategy ETF (NYSE:BITO).
Via
Benzinga
Topics
ETFs
Veracyte to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
December 12, 2023
From
Veracyte, Inc.
Via
Business Wire
Real-World Data Presented at SUO 2023 Show that Veracyte’s Decipher Genomic Classifier Identifies Patients Whose Prostate Cancer is Likely to Progress
December 01, 2023
From
Veracyte, Inc.
Via
Business Wire
The Latest Analyst Ratings for Veracyte
October 20, 2023
Via
Benzinga
Clinical Validation Data Published in CHEST Demonstrate that Veracyte’s Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment for Patients with Lung Nodules
November 29, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces Seven Posters Highlighting Clinical Value of Decipher Prostate Genomic Testing To be Presented at SUO 2023
November 22, 2023
From
Veracyte, Inc.
Via
Business Wire
Are You A Trader Or Investor: Biotech Momentum Is Picking Up
November 20, 2023
ETFs have not helped as portfolio fillers but they can identify trends. We should play this rally out of a biotech bear market.
Via
Talk Markets
Topics
ETFs
Veracyte Announces Third Quarter 2023 Financial Results
November 07, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces In Vitro Diagnostic Agreement with Illumina to Broaden Availability of Its Tests for Patients Globally
November 07, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Participate in the Stephens Annual Investment Conference
November 02, 2023
From
Veracyte, Inc.
Via
Business Wire
Earnings Scheduled For November 7, 2023
November 07, 2023
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter.
Via
Benzinga
Veracyte Announces SITC 2023 Presentations Offering New Insight into Immuno-oncology Drug Development
October 27, 2023
From
Veracyte, Inc.
Via
Business Wire
7 Undervalued Stocks That Analysts Love Right Now
October 26, 2023
With many investors concerned about what may lie ahead in the market, these potentially de-risked undervalued stocks may be ideal.
Via
InvestorPlace
Veracyte to Release Third Quarter 2023 Financial Results on November 7, 2023
October 17, 2023
From
Veracyte, Inc.
Via
Business Wire
New Data Presented at CHEST 2023 Demonstrate the Clinical Utility of Veracyte’s Envisia Genomic Classifier for Patients with Interstitial Lung Disease
October 12, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte Stock Is Volatile After-Hours - Here's Why
October 04, 2023
Veracyte, Inc. (NASDAQ: VCYT) shares are volatile after-hours on Wednesday after the company announced that new data from a phase 3 trial validates the value of the Decipher Prostate Genomic Classifier...
Via
Benzinga
New Data from Phase 3 Trial Further Validate Prognostic Value of Veracyte’s Decipher Prostate Genomic Classifier
October 04, 2023
From
Veracyte, Inc.
Via
Business Wire
New Data Presented at the 2023 ATA Annual Meeting Demonstrate that Veracyte’s Afirma-Based Testing Can Uncover Key Molecular Hallmarks of Thyroid Cancer
September 28, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces Multiple Studies Reinforcing the Value of Decipher Prostate Testing Will Be Presented at ASTRO 2023
September 28, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte Names Phillip G. Febbo, M.D., as Chief Scientific Officer and Chief Medical Officer
September 27, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces Novel Afirma-Based Findings that Advance Molecular Understanding of Thyroid Cancer to Be Presented at the 2023 ATA Annual Meeting
September 21, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte Names Marie-Claire Taine, Ph.D., as General Manager of Its IVD Business Unit To Advance Global Expansion of the Company’s Tests
September 07, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte and Gustave Roussy Announce Collaboration to Help Biopharmaceutical Companies Accelerate Development of Novel Cancer Therapies
September 06, 2023
From
Veracyte, Inc.
Via
Business Wire
Is This Underfollowed Genetic Diagnostics Stock a Buy for Growth Investors?
September 02, 2023
The genetic test maker is rapidly increasing test volumes.
Via
The Motley Fool
Veracyte to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
August 29, 2023
From
Veracyte, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.